Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Colorectal Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 248 articles:
HTML format



Single Articles


    July 2020
  1. TARAZONA N, Roda D, Rosello S, Huerta M, et al
    New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing.
    Ann Oncol. 2020 Jul 22. pii: S0923-7534(20)39950.
    PubMed    


  2. ARGILES G, Tabernero J, Labianca R, Hochhauser D, et al
    Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
    Ann Oncol. 2020 Jul 10. pii: S0923-7534(20)39932.
    PubMed    


  3. PAGES F, Andre T, Taieb J, Vernerey D, et al
    Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39900.
    PubMed    


    June 2020
  4. RODA D, Rosello S, Huerta M, Cervantes A, et al
    Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.
    Ann Oncol. 2020 Jun 13. pii: S0923-7534(20)39872.
    PubMed    


  5. MAURI G, Arena S, Siena S, Bardelli A, et al
    The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer.
    Ann Oncol. 2020 Jun 5. pii: S0923-7534(20)39869.
    PubMed     Abstract available


  6. VAN CUTSEM E, Danielewicz I, Saunders MP, Pfeiffer P, et al
    Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.
    Ann Oncol. 2020 Jun 1. pii: S0923-7534(20)39866.
    PubMed     Abstract available


    April 2020
  7. YOSHINO T, Lenz HJ
    Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Giuseppe et al.
    Ann Oncol. 2020 Apr 30. pii: S0923-7534(20)39311.
    PubMed    


  8. PAGES F, Andre T, Taieb J, Vernerey D, et al
    Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Ann Oncol. 2020 Apr 12. pii: S0923-7534(20)36415.
    PubMed     Abstract available


  9. COLLOCA G, Venturino A, Guarneri D
    Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil.
    Ann Oncol. 2020 Apr 9. pii: S0923-7534(20)36409.
    PubMed    


    February 2020
  10. BRIDGEWATER J
    Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)35948.
    PubMed    


  11. ANDRE T, Vernerey D, Im SA, Bodoky G, et al
    Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
    Ann Oncol. 2020;31:246-256.
    PubMed     Abstract available


    January 2020
  12. LEE H, Sha D, Foster NR, Shi Q, et al
    Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
    Ann Oncol. 2020 Jan 25. pii: S0923-7534(20)35944.
    PubMed     Abstract available


  13. SALEM ME, Yin J, Goldberg RM, Pederson LD, et al
    Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35924.
    PubMed     Abstract available


  14. YOSHINO T, Cleary JM, Van Cutsem E, Mayer RJ, et al
    Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    Ann Oncol. 2020;31:88-95.
    PubMed     Abstract available


  15. HOLCH JW, Held S, Stintzing S, Fischer von Weikersthal L, et al
    Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
    Ann Oncol. 2020;31:72-78.
    PubMed     Abstract available


  16. MARTINELLI E, Ciardiello D, Martini G, Troiani T, et al
    Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
    Ann Oncol. 2020;31:30-40.
    PubMed     Abstract available


  17. KASI PM, Grothey A
    Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
    Ann Oncol. 2020;31:15-16.
    PubMed    


    December 2019
  18. MARMORINO F, Rossini D, Lonardi S, Moretto R, et al
    Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019;30:1969-1977.
    PubMed     Abstract available


    November 2019
  19. STINTZING S, Wirapati P, Lenz HJ, Neureiter D, et al
    Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Ann Oncol. 2019;30:1796-1803.
    PubMed     Abstract available


  20. SVEEN A, Cremolini C, Dienstmann R
    Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
    Ann Oncol. 2019;30:1682-1685.
    PubMed    


  21. TARAZONA N, Gimeno-Valiente F, Gambardella V, Zuniga S, et al
    Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Ann Oncol. 2019;30:1804-1812.
    PubMed     Abstract available


  22. STINTZING S, Wirapati P, Lenz HJ, Neureiter D, et al
    Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Ann Oncol. 2019;30:1796-1803.
    PubMed     Abstract available


  23. SVEEN A, Cremolini C, Dienstmann R
    Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
    Ann Oncol. 2019;30:1682-1685.
    PubMed    


    October 2019
  24. MARMORINO F, Rossini D, Lonardi S, Moretto R, et al
    Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019 Oct 1. pii: 5579862. doi: 10.1093.
    PubMed     Abstract available


  25. DIENSTMANN R, Villacampa G, Sveen A, Mason MJ, et al
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Ann Oncol. 2019;30:1622-1629.
    PubMed     Abstract available


  26. NYAMUNDANDA G, Fontana E, Sadanandam A
    Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
    Ann Oncol. 2019;30:1538-1540.
    PubMed    


    September 2019
  27. TARAZONA N, Gimeno-Valiente F, Gambardella V, Zuniga S, et al
    Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Ann Oncol. 2019 Sep 28. pii: 5574388. doi: 10.1093.
    PubMed     Abstract available


  28. RODA D, Rosello S, Cervantes A
    Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.
    Ann Oncol. 2019;30:1409-1410.
    PubMed    


  29. TAIEB J, Shi Q, Pederson L, Alberts S, et al
    Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Ann Oncol. 2019;30:1466-1471.
    PubMed     Abstract available


    August 2019
  30. NYAMUNDANDA G, Fontana E, Sadanandam A
    Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
    Ann Oncol. 2019 Aug 29. pii: 5556307. doi: 10.1093.
    PubMed    


  31. DIENSTMANN R, Villacampa G, Sveen A, Mason MJ, et al
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Ann Oncol. 2019 Aug 27. pii: 5555302. doi: 10.1093.
    PubMed     Abstract available


  32. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548994. doi: 10.1093.
    PubMed    


  33. GLYNNE-JONES R
    Extending the interval to surgery in rectal cancer and filling the time with chemotherapy-how much is enough?
    Ann Oncol. 2019;30:1188-1190.
    PubMed    


    July 2019
  34. TAIEB J, Shi Q, Pederson L, Alberts S, et al
    Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies.
    Ann Oncol. 2019 Jul 3. pii: 5527754. doi: 10.1093.
    PubMed     Abstract available


  35. SCHROCK AB, Ouyang C, Sandhu J, Sokol E, et al
    Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Ann Oncol. 2019;30:1096-1103.
    PubMed     Abstract available


  36. HAMFJORD J, Guren TK, Dajani O, Johansen JS, et al
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Ann Oncol. 2019;30:1088-1095.
    PubMed     Abstract available


  37. KOLESNIK O, Lukashenko A, Ostapenko Y, Chorna N, et al
    Laparoscopic liver resection in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv99.
    PubMed    


  38. GUETTITI TOUNSI H, Wider D, Ben Ayed I, Habbachi A, et al
    Colorectal cancer in young Tunisian patients: clinical, histopathological and RAS testing data.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    


  39. DASH P, Topi G, Sjolander A
    To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    


  40. ALIANE H, Ghomari-Bezzar S
    The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed    


  41. LUKASHENKO A, Kolesnik O, Chorna N, Ostapenko Y, et al
    Simultaneous lungs and liver resections in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv98-iv99.
    PubMed    


  42. ALIANE H, Ghomari-Bezzar S
    Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed    


  43. AYARI J, Karrit S, Guesmi R, Zribi A, et al
    Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A prospective study in 60 patients in Tunisia.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed    


  44. DIAZ C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, et al
    Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed    


  45. ROSSAT S, Lefevre M, Le Berre N, Dorel M, et al
    Turnaround time < 7 days with a fully automated assay for RAS mutations in metastatic colorectal cancer: a pilot project in real-life conditions.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed    


  46. JAVED H, Faisal M, Khan J, Anwar H, et al
    Higher expression of ERBB2, KRAS and down-regulation of APC, NF1 genes in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv94.
    PubMed    


  47. HISAMATSU A, Ikusue T, Toshima H, Kobayashi K, et al
    Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy.
    Ann Oncol. 2019;30 Suppl 4:iv93.
    PubMed    


  48. BELAID I, Khechine W, Saad A, Fki A, et al
    Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia.
    Ann Oncol. 2019;30 Suppl 4:iv93-iv94.
    PubMed    


  49. VITALE P, Zanaletti N, Vitiello P, Martinelli E, et al
    Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data.
    Ann Oncol. 2019;30 Suppl 4:iv91.
    PubMed    


  50. DE FALCO V, Vitiello P, Giunta E, Ciardiello D, et al
    Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience.
    Ann Oncol. 2019;30 Suppl 4:iv90.
    PubMed    


  51. MARAVIC Z, Benedict A, Komlos K, Lemmens L, et al
    Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey.
    Ann Oncol. 2019;30 Suppl 4:iv90-iv91.
    PubMed    


  52. TOMAS T, Nogueira-Costa G, Eiriz I, Vitorino M, et al
    Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal.
    Ann Oncol. 2019;30 Suppl 4:iv88.
    PubMed    


  53. D'ARCANGELO M, Buonerba C, Avallone A, Dazzi C, et al
    The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study.
    Ann Oncol. 2019;30 Suppl 4:iv87-iv88.
    PubMed    


  54. BENSI M, Calegari M, Basso M, Orlandi A, et al
    Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study).
    Ann Oncol. 2019;30 Suppl 4:iv87.
    PubMed    


  55. RODRIGUEZ-COBOS J, Vinal D, Poves C, Fernandez-Acenero M, et al
    DeltaNp73 and Delta133p53 in liquid biopsy as early diagnostic markers for colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv86-iv87.
    PubMed    


  56. BEN NASR S, Alibi S, Msekni I, Zribi A, et al
    Role of TILS in predicting evolution of metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv85.
    PubMed    


  57. MIHAYLOVA Z, Ivanova D, Mihaylova G, Tasinov O, et al
    Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease.
    Ann Oncol. 2019;30 Suppl 4:iv81-iv82.
    PubMed    


  58. PRETTA A, Lai E, Liscia N, Impera V, et al
    Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience.
    Ann Oncol. 2019;30 Suppl 4:iv81.
    PubMed    


  59. ZHENG Q, Peng P
    Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv8.
    PubMed    


  60. BASILE D, Pelizzari G, Di Nardo P, Corvaja C, et al
    The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA).
    Ann Oncol. 2019;30 Suppl 4:iv79.
    PubMed    


  61. VAN CUTSEM E, Shitara K, Deng W, Vaury A, et al
    Gevokizumab, an interleukin-1beta (IL-1beta) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): "first-in-cancer" phase Ib study.
    Ann Oncol. 2019;30 Suppl 4:iv77-iv78.
    PubMed    


  62. RUIZ-VOZMEDIANO J, Gutierrez-Martinez A, Postigo-Martin P, Cruz-Fernandez M, et al
    Efficacy of a therapeutic exercise program on autonomic nervous system function, cardiac function and functional capacity in colorectal cancer survivors: a randomized controlled pilot study.
    Ann Oncol. 2019;30 Suppl 4:iv77.
    PubMed    


  63. ODENY T, Farha N, Hildebrand H, Allen J, et al
    Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv73.
    PubMed    


  64. CALDERILLO-RUIZ G, Heredia D, Lopez H, Carbajal B, et al
    Retroperitoneal lymph node metastases as a prognosis factor in overall survival in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv72.
    PubMed    


  65. NAGASAKA T, Tanioka H, Nyuya A, Katata Y, et al
    Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 4:iv71.
    PubMed    


  66. MARINHO J, Neto E, Leao I, Silva J, et al
    Liquid biopsy for RAS mutational status analysis in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv69-iv70.
    PubMed    


  67. BEN KRIDIS W, Mnif A, Khmiri S, Feki J, et al
    Right-sided versus left-sided metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv68.
    PubMed    


  68. CIPRIANO A, Tavares A, Soares A, Mesquita A, et al
    The importance of laterality in colorectal cancer predicting response to therapeutics - retrospective study evaluating differences between right and left colon in stage IV colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv67-iv68.
    PubMed    


  69. OMRCEN T, Katic A, Tomic S, Eterovic D, et al
    Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
    Ann Oncol. 2019;30 Suppl 4:iv65.
    PubMed    


  70. NAZARIAN A, Sureshbabu S, Berman N, Wolf D, et al
    RENCA macrobead therapy (RMB): A biological-systems approach to metastatic colorectal cancer [U.S. FDA BB-IND 10091].
    Ann Oncol. 2019;30 Suppl 4:iv64.
    PubMed    


  71. BURZ C, Bojan A, Balacescu L, Lisencu C, et al
    Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv63-iv64.
    PubMed    


  72. SANCHEZ-CAMACHO A, Herrero Rivera D, Carrasco I, Limon M, et al
    Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution.
    Ann Oncol. 2019;30 Suppl 4:iv62.
    PubMed    


  73. PREJAC J, Kekez D, Belev B, Plestina S, et al
    Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer: a single-centre retrospective cohort analysis of 186 patients.
    Ann Oncol. 2019;30 Suppl 4:iv62.
    PubMed    


  74. TAMPAKIS A, Tampaki E, Nonni A, Patsouris E, et al
    L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease.
    Ann Oncol. 2019;30 Suppl 4:iv60.
    PubMed    


  75. FORNER S, Summers J, Hill M, Mikropoulos C, et al
    Which patients on chemotherapy for colorectal cancer should be anticoagulated?
    Ann Oncol. 2019;30 Suppl 4:iv6.
    PubMed    


  76. WONG S, Chiang C, Yeung S, Lee S, et al
    The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases.
    Ann Oncol. 2019;30 Suppl 4:iv58.
    PubMed    


  77. BOUSAHBA A, Behourah Z
    Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab.
    Ann Oncol. 2019;30 Suppl 4:iv56.
    PubMed    


  78. BAE J, Kye B, Lee Y, Lee I, et al
    Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv56.
    PubMed    


  79. GRIDNEV D, Trandofilov M, Zhevelyuk A, Islamova D, et al
    The role of combined treatment of metastatic colorectal cancer in patients with liver metastases.
    Ann Oncol. 2019;30 Suppl 4:iv55.
    PubMed    


  80. KR A, P SS, Kumar C R
    Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv54.
    PubMed    


  81. KR A, P SS, Kumar C R
    Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Ann Oncol. 2019;30 Suppl 4:iv54.
    PubMed    


  82. DUARTE S, Grilo I, Ladeira K, Pimenta J, et al
    Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences.
    Ann Oncol. 2019;30 Suppl 4:iv53.
    PubMed    


  83. JAROSZ M, Rychlik E
    Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland.
    Ann Oncol. 2019;30 Suppl 4:iv53.
    PubMed    


  84. APARICIO J, Virgili A, Capdevila J, Munoz Boza F, et al
    Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).
    Ann Oncol. 2019;30 Suppl 4:iv52.
    PubMed    


  85. KR A, P SS, Kumar C R
    Complete peritonectomy versus selective peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes.
    Ann Oncol. 2019;30 Suppl 4:iv52.
    PubMed    


  86. DE TORO CARMENA M, Ortega Moran L, Garcia Adrian S, Castanon Lopez C, et al
    Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients.
    Ann Oncol. 2019;30 Suppl 4:iv51-iv52.
    PubMed    


  87. JAROSZ M, Rychlik E
    Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland.
    Ann Oncol. 2019;30 Suppl 4:iv50.
    PubMed    


  88. PARK Y, Lee K, Lee J, Oh S, et al
    Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv5.
    PubMed    


  89. FORMICA V, Nardecchia A, Morelli C, Lucchetti J, et al
    A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv48.
    PubMed    


  90. MARTINEZ-LAGO N, Carmona Campos M, Gonzalez Villarroel P, Salgado Fernandez M, et al
    Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.
    Ann Oncol. 2019;30 Suppl 4:iv42-iv43.
    PubMed    


  91. BOUDINAR F, Larbaoui B
    Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases.
    Ann Oncol. 2019;30 Suppl 4:iv41-iv42.
    PubMed    


  92. ABDALLAH E, Souzae Silva V, Aguiar S Jr, Takahashi R, et al
    Circulating tumor cells levels correlate with carcinoembryonic antigen in patients with high-risk colon cancer who experienced disease progression.
    Ann Oncol. 2019;30 Suppl 4:iv41.
    PubMed    


  93. CALDERILLO-RUIZ G, Lopez H, Herrera M, Trejo E, et al
    Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv40-iv41.
    PubMed    


  94. CALDERILLO-RUIZ G, Lopez H, Padilla A, Diaz C, et al
    Surgery specialization as a prognostic factor in colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv40.
    PubMed    


  95. CALDERILLO-RUIZ G, Lopez H, Diaz C, Ruiz-Garcia E, et al
    Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III.
    Ann Oncol. 2019;30 Suppl 4:iv39.
    PubMed    


  96. RICCI V, Falletta A, Granetto C, Paccagnella M, et al
    Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib.
    Ann Oncol. 2019;30 Suppl 4:iv38.
    PubMed    


  97. CALEGARI M, Zurlo I, Basso M, Orlandi A, et al
    Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study).
    Ann Oncol. 2019;30 Suppl 4:iv37-iv38.
    PubMed    


  98. VERMORKEN J, Cervantes A, Morsing P, Johansson K, et al
    A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv36.
    PubMed    


  99. SUN G, Gao P, Jia J, Zhang L, et al
    Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure.
    Ann Oncol. 2019;30 Suppl 4:iv36.
    PubMed    


  100. FEDYANIN M, Chubenko V, Belonogov A, Beluhin S, et al
    Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study.
    Ann Oncol. 2019;30 Suppl 4:iv35.
    PubMed    


  101. YU H, Yao X, Meng X
    A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism.
    Ann Oncol. 2019;30 Suppl 4:iv35-iv36.
    PubMed    


  102. KIM C, Kim W, Han Y, Kim J, et al
    Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv35.
    PubMed    


  103. GHIDINI M, Hahne J, Senti C, Lampis A, et al
    Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
    Ann Oncol. 2019;30 Suppl 4:iv34-iv35.
    PubMed    


  104. ELBAIOMY M, Waheed A, Elkhodary T
    Prognostic value of lymph node ratio in lymph node-invaded colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv34.
    PubMed    


  105. CUNHA R, Menezes M, Fernandes R, Oliveira A, et al
    Stage IIa colon cancer: adjuvant chemotherapy in real life.
    Ann Oncol. 2019;30 Suppl 4:iv32.
    PubMed    


  106. GIULIANI J, Bonetti A
    The onset of grade>/=3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil.
    Ann Oncol. 2019;30 Suppl 4:iv31.
    PubMed    


  107. LOMBARDI P, Marandino L, De Luca E, Zichi C, et al
    Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018.
    Ann Oncol. 2019;30 Suppl 4:iv29.
    PubMed    


  108. TILBY M, Escola C, Ellison C, Narramneni L, et al
    Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience.
    Ann Oncol. 2019;30 Suppl 4:iv27.
    PubMed    


  109. ISHIGURO A, Yuki S, Takahashi N, Shichinohe T, et al
    North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003).
    Ann Oncol. 2019;30 Suppl 4:iv24.
    PubMed    


  110. FERNANDEZ MONTES A, Martinez Lago N, De la Camara Gomez J, Covela Rua M, et al
    FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.
    Ann Oncol. 2019;30 Suppl 4:iv23-iv24.
    PubMed    


  111. SFAKIANAKI M, Papadaki C, Tzardi M, Trypaki M, et al
    PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv21-iv22.
    PubMed    


  112. ZAREV I, Maksimovic M, Ljubisavljevic R, Bozovic M, et al
    Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv21.
    PubMed    


  113. CHEONG C, Suh K
    Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features.
    Ann Oncol. 2019;30 Suppl 4:iv20.
    PubMed    


  114. ROSATI G, Cordio S, Reggiardo G, Aprile G, et al
    Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies.
    Ann Oncol. 2019;30 Suppl 4:iv19-iv20.
    PubMed    


  115. NOGUEIRA-COSTA G, Fernandes I, Guerra-Pereira N, Gameiro R, et al
    Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role.
    Ann Oncol. 2019;30 Suppl 4:iv18.
    PubMed    


  116. FEDYANIN M, Chekini D, Chubenko V, Tjulandin S, et al
    Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis.
    Ann Oncol. 2019;30 Suppl 4:iv16.
    PubMed    


  117. PAPAMICHAEL D, Kountourakis P, Papanastasopoulos P, Xenophontos E, et al
    Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years.
    Ann Oncol. 2019;30 Suppl 4:iv16.
    PubMed    


  118. KOGAN Y, Elishmereni M, Taub E, Agur Z, et al
    (late submission poster) The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv155.
    PubMed    


  119. KOPETZ S, Grothey A, Van Cutsem E, Yaeger R, et al
    BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv154.
    PubMed    


  120. CASADEI GARDINI A, Gelsomino F, Spallanzani A, Tamburini E, et al
    Is there an optimal choice in refractory colorectal cancer? A network meta-analysis.
    Ann Oncol. 2019;30 Suppl 4:iv14.
    PubMed    


  121. ANGELIS V, Young T, Vasiliadou I, Hill M, et al
    Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv14.
    PubMed    


  122. CASE A, Arif S
    The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation.
    Ann Oncol. 2019;30 Suppl 4:iv14.
    PubMed    


  123. ARGILES G, Margalef NM, Valladares-Ayerbes M, de Prado JV, et al
    Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv135.
    PubMed    


  124. PIETRANTONIO F, Lobefaro R, Antista M, Miceli R, et al
    A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv135.
    PubMed    


  125. GALON J, Hermitte F, Mlecnik B, Marliot F, et al
    Significant differences in outcome between Immunoscore categories in stage I colon cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv134.
    PubMed    


  126. GAMBARO K, Marques M, McNamara S, du Tertre MC, et al
    Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy.
    Ann Oncol. 2019;30 Suppl 4:iv133.
    PubMed    


  127. ELIZABETH A, Jansen L, Hendrik B, Kloor M, et al
    Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Ann Oncol. 2019;30 Suppl 4:iv132.
    PubMed    


  128. MYER P, Lee J, Madison R, Newberg J, et al
    Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry.
    Ann Oncol. 2019;30 Suppl 4:iv132.
    PubMed    


  129. WATANABE J, Sato T, Kagawa Y, Oki E, et al
    SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv132.
    PubMed    


  130. PFEIFFER P, Glimelius B, Winther S, Qvortrup C, et al
    Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results.
    Ann Oncol. 2019;30 Suppl 4:iv131.
    PubMed    


  131. PARIKH A, Van Seventer E, Boland G, Hartwig A, et al
    Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv131.
    PubMed    


  132. PFEIFFER P, Yilmaz M, Moller S, Zitnjak D, et al
    Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial.
    Ann Oncol. 2019;30 Suppl 4:iv130-iv131.
    PubMed    


  133. GARRALDA E, Fiedler W, Matos I, Rolling C, et al
    Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.
    Ann Oncol. 2019;30 Suppl 4:iv125.
    PubMed    


  134. SALEH M, Cassier P, Eberst L, Naik G, et al
    Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study.
    Ann Oncol. 2019;30 Suppl 4:iv124.
    PubMed    


  135. VAN CUTSEM E, Machiels J, Van den Eynde M, Prenen H, et al
    Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv124-iv125.
    PubMed    


  136. GEISSLER M, Tannapfel A, Reinacher-Schick A, Martens U, et al
    Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv119-iv120.
    PubMed    


  137. DUCREUX M, O'Connor J, Dochy E, Fiala-Buskies S, et al
    Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv119.
    PubMed    


  138. OSTERLUND P, Lamminmaki A, Soveri L, Algars A, et al
    Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study.
    Ann Oncol. 2019;30 Suppl 4:iv119.
    PubMed    


  139. HOFHEINZ R, Scholten F, Derigs H, Thaler J, et al
    Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113).
    Ann Oncol. 2019;30 Suppl 4:iv118.
    PubMed    


  140. ROSSINI D, Pagani F, Pellino A, Dell'Aquila E, et al
    Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis.
    Ann Oncol. 2019;30 Suppl 4:iv118.
    PubMed    


  141. MAURI G, Kanter K, Fish M, Horick N, et al
    PARP-ness in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv117.
    PubMed    


  142. DAS R, Ou F, Washburn C, Innocenti F, et al
    Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed    


  143. SALVATORE L, Bria E, Sperduti I, Hinke A, et al
    Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies.
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed    


  144. CARDONE C, Blauensteiner B, Moreno-Viedma V, Paul M, et al
    Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS.
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed    


  145. RAIMONDI A, Di Maio M, Peverelli G, Morano F, et al
    Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study.
    Ann Oncol. 2019;30 Suppl 4:iv115.
    PubMed    


  146. LAM K, Ko J, Chan A, Choi H, et al
    Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv115-iv116.
    PubMed    


  147. SUNAKAWA Y, Nakamura M, Ishizaki M, Kataoka M, et al
    RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv114.
    PubMed    


  148. ROSSINI D, Sbrana A, Bergamo F, Manai C, et al
    Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019;30 Suppl 4:iv114-iv115.
    PubMed    


  149. OSTERMAN E, Mezheyeuski A, Sjoblom T, Glimelius B, et al
    Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort.
    Ann Oncol. 2019;30 Suppl 4:iv113.
    PubMed    


  150. VIEITEZ DE PRADO J, Encinas Garcia S, Grande Pulido E, Sanchez Nieto R, et al
    Cost of metastatic colorectal cancer drugs per month of life gained in Spain.
    Ann Oncol. 2019;30 Suppl 4:iv11.
    PubMed    


  151. RADWI A, Asiri I, Asiri M, Khudhayri A, et al
    Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv11-iv12.
    PubMed    


  152. GROTHEY A, Yaeger R, Paez D, Tabernero J, et al
    ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv109.
    PubMed    


  153. SGHAIER S, Rachdi H, Mejri N, Graja B, et al
    How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases.
    Ann Oncol. 2019;30 Suppl 4:iv108-iv109.
    PubMed    


  154. SATAPATHY S, Sjolander A
    15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-alpha dependent phenomenon.
    Ann Oncol. 2019;30 Suppl 4:iv107.
    PubMed    


  155. CARNERERO CORDOBA L, Gonzalez Cebrian I, Rodriguez Gonzalez C, Gonzalez-Flores E, et al
    Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population.
    Ann Oncol. 2019;30 Suppl 4:iv106.
    PubMed    


  156. KIM S, Kim S
    Interleukin-6 induced Lipocalin 2 promotes tumorigenesis from colitis to colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv105-iv106.
    PubMed    


  157. BERRAD S, Oualla K, Nouiyakh L, Erraichi H, et al
    Survival and prognostic factors for stage II colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv105.
    PubMed    


  158. BEKOUACI S, Smaili F
    Are hepatic metastases of colorectal cancer more chemosensitive than other metastatic sites?
    Ann Oncol. 2019;30 Suppl 4:iv104.
    PubMed    


  159. SHIN R, Park J, Jeong S, Heo S, et al
    Clinicopathologic feature of microsatellite stable early-onset colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv104.
    PubMed    


  160. BEKOUACI S, Smaili F
    Clinico-epidemiological profile of colorectal cancer in Algerian patients age 40 and under: Alarming increase in incidence.
    Ann Oncol. 2019;30 Suppl 4:iv103-iv104.
    PubMed    


  161. SIMOES J, Fernandes C, Borges C, Melo R, et al
    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv101.
    PubMed    


  162. STREICH G, Batagelj E, Dimase F, Martinez D, et al
    Home chemotherapy in colorectal cancer: First experience in Argentina.
    Ann Oncol. 2019;30 Suppl 4:iv101.
    PubMed    


  163. ELKHOULY E, Gohar S, Abelela D, Fakhry T, et al
    Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv100-iv101.
    PubMed    


  164. TOPI G, Satapathy S, Dash P, Ehrnstrom R, et al
    High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv100.
    PubMed    


  165. RAMIREZ DAFFOS P, Gonzalez-Astorga B, Jimenez E, Rubiales S, et al
    Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities.
    Ann Oncol. 2019;30 Suppl 4:iv10-iv11.
    PubMed    


  166. MURO K, Uetake H, Tsuchihara K, Shitara K, et al
    PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv10.
    PubMed    


  167. ZOK J, Radecka B, Adamowicz K, Korniluk J, et al
    Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv10.
    PubMed    


  168. KRUCHININA M, Gromov A, Prudnikova I, Shashkov M, et al
    Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics.
    Ann Oncol. 2019;30 Suppl 4:iv1.
    PubMed    


    June 2019
  169. SOUGLAKOS J, Boukovinas I, Kakolyris S, Xynogalos S, et al
    Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherap
    Ann Oncol. 2019 Jun 22. pii: 5522015. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  170. HAMFJORD J, Guren TK, Dajani O, Johansen JS, et al
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.
    Ann Oncol. 2019 May 2. pii: 5482571. doi: 10.1093.
    PubMed     Abstract available


  171. SANTOS C, Azuara D, Vieitez JM, Paez D, et al
    Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Ann Oncol. 2019;30:796-803.
    PubMed     Abstract available


    April 2019
  172. SCHROCK AB, Ouyang C, Sandhu J, Sokol E, et al
    Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Ann Oncol. 2019 Apr 30. pii: 5482063. doi: 10.1093.
    PubMed     Abstract available


  173. FONTANA E, Eason K, Cervantes A, Salazar R, et al
    Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.
    Ann Oncol. 2019;30:520-527.
    PubMed     Abstract available


  174. GUNTER MJ, Alhomoud S, Arnold M, Brenner H, et al
    Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
    Ann Oncol. 2019;30:510-519.
    PubMed     Abstract available


    March 2019
  175. SANTOS C, Azuara D, Vieitez JM, Paez D, et al
    Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Ann Oncol. 2019 Mar 6. pii: 5370172. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  176. FONTANA E, Eason K, Cervantes A, Salazar R, et al
    Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials.
    Ann Oncol. 2019 Feb 23. pii: 5364014. doi: 10.1093.
    PubMed     Abstract available


  177. GUNTER MJ, Alhomoud S, Arnold M, Brenner H, et al
    Meeting Report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.
    Ann Oncol. 2019 Feb 5. pii: 5307027. doi: 10.1093.
    PubMed     Abstract available


  178. SINGH AV
    21PEvaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
    Ann Oncol. 2019;30.
    PubMed    


  179. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
    20PNischarin expression in colon cancer.
    Ann Oncol. 2019;30.
    PubMed    


  180. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
    19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
    Ann Oncol. 2019;30.
    PubMed    


  181. SHITARA K, Yamanaka T, Denda T, Tsuji Y, et al
    REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
    Ann Oncol. 2019;30:259-265.
    PubMed     Abstract available


  182. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2019;30:157-159.
    PubMed    


  183. SINGH AV
    Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed    


  184. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
    Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
    Ann Oncol. 2019;30 Suppl 1:i7.
    PubMed    


  185. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
    Nischarin expression in colon cancer.
    Ann Oncol. 2019;30 Suppl 1:i7-i8.
    PubMed    


    January 2019
  186. VIDAL J, Bellosillo B, Santos Vivas C, Garcia-Alfonso P, et al
    Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
    Ann Oncol. 2019 Jan 23. pii: 5299439. doi: 10.1093.
    PubMed     Abstract available


    December 2018
  187. SHITARA K, Yamanaka T, Denda T, Tsuji Y, et al
    REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients.
    Ann Oncol. 2018 Dec 3. pii: 5227619. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  188. SIRAVEGNA G, Bardelli A
    Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
    Ann Oncol. 2018 Nov 26. pii: 5209692. doi: 10.1093.
    PubMed    


    October 2018
  189. WANG Y, Jones JC, Kipp BR, Grothey A, et al
    Activity of EGFR Antibody in Non-V600 BRAF Mutant Metastatic Colorectal Cancer.
    Ann Oncol. 2018 Oct 26. pii: 5145082. doi: 10.1093.
    PubMed    


    September 2018
  190. MOOI JK, Wirapati P, Asher R, Lee CK, et al
    The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Ann Oncol. 2018 Sep 21. pii: 5104878. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  191. MAURI G, Bencardino K, Sartore-Bianchi A, Siena S, et al
    Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.
    Ann Oncol. 2018 Jul 28. pii: 5061139. doi: 10.1093.
    PubMed    


  192. VAN CUTSEM E, Yoshino T, Lenz HJ, Lonardi S, et al
    Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
    Ann Oncol. 2018 Jul 13. pii: 5053583. doi: 10.1093.
    PubMed     Abstract available


  193. OVERMAN MJ, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048416. doi: 10.1093.
    PubMed    


    June 2018
  194. SARTORE-BIANCHI A, Siena S
    The right chance for temozolomide in metastatic colorectal cancer?
    Ann Oncol. 2018 Jun 25. pii: 5044274. doi: 10.1093.
    PubMed    


  195. SOBRERO A, Douillard JY
    Reply to the Letter to the Editor: "The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?" By P. Trendsz et al.
    Ann Oncol. 2018 Jun 15. pii: 5038506. doi: 10.1093.
    PubMed    


  196. TAN RYC, Camat MD, Ng M, Lim TH, et al
    HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients.
    Ann Oncol. 2018 Jun 3. pii: 5001837. doi: 10.1093.
    PubMed    


    May 2018
  197. MORANO F, Corallo S, Niger M, Barault L, et al
    Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Ann Oncol. 2018 May 31. pii: 5026003. doi: 10.1093.
    PubMed     Abstract available


  198. TRENSZ P, Calvel L, Kurtz JE
    The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 May 22. pii: 5001429. doi: 10.1093.
    PubMed    


    April 2018
  199. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
    Ann Oncol. 2018 Apr 30. pii: 4990353. doi: 10.1093.
    PubMed    


  200. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
    Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
    Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
    PubMed     Abstract available


  201. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
    Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.
    Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
    PubMed     Abstract available


  202. SANTOS C, Sanz-Pamplona R, Salazar R
    RET-fusions: a novel paradigm in colorectal cancer.
    Ann Oncol. 2018 Apr 10. pii: 4965879. doi: 10.1093.
    PubMed    


  203. SIENA S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, et al
    Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
    Ann Oncol. 2018 Apr 6. pii: 4962457. doi: 10.1093.
    PubMed     Abstract available


  204. MASUISHI T, Taniguchi H, Sugiyama K, Kato K, et al
    Eribulin in BRAF V600E mutant metastatic colorectal cancer: Case series and potential rationale.
    Ann Oncol. 2018 Apr 4. pii: 4959907. doi: 10.1093.
    PubMed    


    March 2018
  205. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2018 with focus on colorectal cancer.
    Ann Oncol. 2018 Mar 19. pii: 4935197. doi: 10.1093.
    PubMed     Abstract available


  206. MONTAGUT C, Tsui DW, Diaz LA Jr.
    Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?
    Ann Oncol. 2018 Mar 14. pii: 4937227. doi: 10.1093.
    PubMed    


  207. SMEBY J, Sveen A, Merok MA, Danielsen SA, et al
    CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Ann Oncol. 2018 Mar 5. pii: 4922418. doi: 10.1093.
    PubMed     Abstract available


  208. VIVANCOS A, Elez E, Salazar R
    Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
    Ann Oncol. 2018;29:532-534.
    PubMed    


  209. SCHOU JV, Larsen FO, Sorensen BS, Abrantes R, et al
    Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
    Ann Oncol. 2018;29:610-615.
    PubMed     Abstract available


    February 2018
  210. ARNOLD D, Prager GW, Quintela A, Stein A, et al
    Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Ann Oncol. 2018 Feb 14. pii: 4857261. doi: 10.1093.
    PubMed     Abstract available


  211. BACHET JB, Bouche O, Taieb J, Dubreuil O, et al
    RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
    Ann Oncol. 2018 Feb 9. pii: 4846852. doi: 10.1093.
    PubMed     Abstract available


  212. CARR PR, Alwers E, Bienert S, Weberpals J, et al
    Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses.
    Ann Oncol. 2018 Feb 9. pii: 4846850. doi: 10.1093.
    PubMed     Abstract available


  213. SOBRERO A, Grothey A, Iveson T, Labianca R, et al
    The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 Feb 9. pii: 4846853. doi: 10.1093.
    PubMed     Abstract available


  214. WILLIS JA, Vilar E
    Pharmacogenomics: time to rethink its role in precision medicine.
    Ann Oncol. 2018;29:293-295.
    PubMed    


    January 2018
  215. SOBHANI I, Itti E, Luciani A, Baumgaertner I, et al
    Colorectal Cancer (CRC) Monitoring by Six-Monthly 18FDG-PET/CT: An Open-Label Multicentre Randomised Trial.
    Ann Oncol. 2018 Jan 22. pii: 4819113. doi: 10.1093.
    PubMed     Abstract available


  216. CARMELIET P, Li X, Treps L, Conradi LC, et al
    RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients.
    Ann Oncol. 2018 Jan 19. pii: 4817343. doi: 10.1093.
    PubMed    


  217. PARK JH, McMillan DC
    Outcome in colorectal cancer - tumour, stroma and so much more.
    Ann Oncol. 2018 Jan 8. pii: 4792956. doi: 10.1093.
    PubMed    


  218. DELL'AQUILA E, Cremolini C, Zeppola T, Lonardi S, et al
    Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Ann Oncol. 2018 Jan 8. pii: 4793700. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  219. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Abstract available


  220. DANIELSEN HE, Hveem TS, Domingo E, Pradhan M, et al
    Prognostic markers for colorectal cancer; estimating ploidy and stroma.
    Ann Oncol. 2017 Dec 27. pii: 4779924. doi: 10.1093.
    PubMed     Abstract available


  221. YAMADA Y, Denda T, Gamoh M, Iwanaga I, et al
    S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial.
    Ann Oncol. 2017 Dec 27. pii: 4779925. doi: 10.1093.
    PubMed     Abstract available


  222. GONG J, Tian J, Lou J, Wang X, et al
    A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267.
    Ann Oncol. 2017 Dec 18. pii: 4756051. doi: 10.1093.
    PubMed     Abstract available


  223. ORDONEZ-ME JM, Walter V, Schottker B, Jenab M, et al
    Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
    Ann Oncol. 2017 Dec 13. pii: 4735153. doi: 10.1093.
    PubMed     Abstract available


  224. TABERNERO J, Hozak RR, Yoshino T, Cohn AL, et al
    Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study.
    Ann Oncol. 2017 Dec 7. pii: 4708229. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  225. YOSHINO T, Arnold D, Taniguchi H, Pentheroudakis G, et al
    Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Ann Oncol. 2017 Nov 16. doi: 10.1093.
    PubMed     Abstract available


  226. ABAD A, Martinez-Balibrea E, Vieitez JM, Orduna VA, et al
    Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Abstract available


  227. DIENSTMANN R, Guinney J
    Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.
    Ann Oncol. 2017;28:2889-2890.
    PubMed    


    October 2017
  228. OVERMAN M, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Abstract available


  229. TARAZONA N, Cervantes A
    Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed    


  230. SCIALLERO S, Battistuzzi L, Varesco L
    Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
    Ann Oncol. 2017;28:2620-2621.
    PubMed    


  231. CASADEI GARDINI A, Valgiusti M, Passardi A, Frassineti GL, et al
    Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?
    Ann Oncol. 2017;28:2620.
    PubMed    


    September 2017
  232. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
    Ann Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Abstract available


  233. CREMOLINI C, Morano F, Moretto R, Berenato R, et al
    Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Abstract available


  234. GARCIA-FONCILLAS J, Alba E, Aranda E, Diaz-Rubio E, et al
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Abstract available


  235. SIENA S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, et al
    Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Abstract available


  236. SOBRERO A, Damiani A
    Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
    Ann Oncol. 2017;28:2043-2044.
    PubMed    


  237. WEI Q, Ye Z, Zhong X, Li L, et al
    Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
    Ann Oncol. 2017;28:2135-2141.
    PubMed     Abstract available


  238. GOEY KKH, Elias SG, van Tinteren H, Lacle MM, et al
    Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Ann Oncol. 2017;28:2128-2134.
    PubMed     Abstract available


    August 2017
  239. NORMANNO N, Esposito Abate R, Lambiase M, Forgione L, et al
    RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Ann Oncol. 2017 Aug 7. doi: 10.1093.
    PubMed     Abstract available


  240. BERGER MD, Stintzing S, Heinemann V, Yang D, et al
    Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Abstract available


    July 2017
  241. SANZ-GARCIA E, Argiles G, Elez E, Tabernero J, et al
    BRAF mutant Colorectal Cancer: prognosis, treatment and new perspectives.
    Ann Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  242. SCHLESINGER S, Aleksandrova K, Abar L, Vieria AR, et al
    Adult weight gain and colorectal adenomas-a systematic review and meta-analysis.
    Ann Oncol. 2017;28:1217-1229.
    PubMed     Abstract available


    May 2017
  243. OTT PA, Piha-Paul SA, Munster P, Pishvaian MJ, et al
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
    Ann Oncol. 2017;28:1036-1041.
    PubMed     Abstract available


    March 2017
  244. ROMBOUTS AJM, Hugen N, Elferink MAG, Feuth T, et al
    Incidence of second tumors after treatment with or without radiation for rectal cancer.
    Ann Oncol. 2017;28:535-540.
    PubMed     Abstract available


    February 2017
  245. PATEL UB, Brown G, Machado I, Santos-Cores J, et al
    MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Ann Oncol. 2017;28:344-353.
    PubMed     Abstract available


  246. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Abstract available


  247. GLYNNE-JONES R
    Adding extra dimensions in rectal cancer theory.
    Ann Oncol. 2017;28:198-200.
    PubMed    


    January 2017
  248. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
    Ann Oncol. 2017;28:9-10.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: